Headquartered in Wayne, PA Fiscal year ends December NASDAQ: ACRS aclaristx.com
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates for immuno-inflammatory diseases, targeting patients who lack satisfactory treatment options. The company operates two revenue-generating segments: contract research services and licensing of its proprietary technology. Its pipeline spans biologics and kinase inhibitors. Key programs include ATI-052, a bispecific anti-TSLP/IL-4Rα antibody being evaluated in atopic dermatitis, asthma, and eosinophilic esophagitis; bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2 for atopic dermatitis; modzatinib (ATI-2138), a selective ITK/JAK3 inhibitor being developed for lichen planus; and ATI-9494, a dual ITK/TXK inhibitor in preclinical development. The company generates modest revenue from licensing agreements with Eli Lilly and Sun Pharma, as well as contract research services, while primarily funding operations through equity financing. Updated
Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market…
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including BP, Conagra Brands, Mattel, Norwegian Cruise Line, PepsiCo and UnitedHealth.
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.
Chris Lange Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates for immuno-inflammatory diseases, targeting patients who lack satisfactory treatment options.
The Wall Street consensus 12-month price target for ACRS is $10.18.
